Table 1.

Human Papillomavirus (HPV) Genotyping Results, Categorized According to Cervical Cancer Risk, and p16 Immunohistochemistry (IHC) Results (p16 IHC Positive [p16⁺] or Negative [p16⁻]) for Biopsy Diagnosis by the Community Pathologist of Negative, Cervical Intraepithelial Neoplasia (CIN) 1, CIN2, and CIN3.

HPV Categoriesa	Diagnosis
	Negative				CIN1				CIN2				CIN3				P trend b	SCC
	p16 IHC Negative		p16 IHC Positive		p16 IHC Negative		p16 IHC Positive		p16 IHC Negative		p16 IHC Positive		p16 IHC Negative		p16 IHC Positive			All
	N	% Col	N	% Col	N	% Col	N	% Col	N	% Col	N	% Col	N	% Col	N	% Col		N	% Col
HPV16	8	3.1	1	4.8	32	4.7	35	14.1	91	21.4	415	38.2	41	36.3	617	56.3	<.001	43	58.9
HPV18/45	5	1.9	2	9.5	24	3.5	25	10.1	29	6.8	82	7.5	8	7.1	57	5.2	<.001	10	13.7
Other high riskc	21	8.0	7	33.3	142	20.7	128	51.6	163	38.4	496	45.6	36	31.9	354	32.3	<.001	10	13.7
Intermediate riskd	9	3.4	2	9.5	54	7.9	28	11.3	29	6.8	56	5.2	3	2.7	31	2.8	<.001	2	2.7
Low riske	4	1.5	0	0.0	35	5.1	4	1.6	18	4.2	7	0.6	4	3.5	3	0.3	.0097	1	1.4
HPV negative	215	82.1	9	42.9	399	58.2	28	11.3	95	22.4	31	2.9	21	18.6	33	3.0	<.001	7	9.6
Total	262	100	21	100	686	100	248	100	425	100	1087	100	113	100	1095	100	<.001	73	100
P trend f	<.001				<.001				<.001				<.001

Abbreviations: NA, not applicable; SCC, squamous cell carcinoma.

Results for all SCCs are shown for reference. “% Col” is the column percentage, that is, the number in cell divided by the total column number.

^aDefined hierarchically according to cancer risk.

^bTest of trend for testing p16 IHC positivity across diagnoses (excluding cancer) for each HPV risk group.

^cHPV31, 33, 35, 39, 51, 52, 56, 58, 59, and 68.

^dHPV26, 53, 66, 67, 70, 73, and 82.

^eHPV6, 11, 40, 42, 54, 55, 61, 62, 64, 69, 71, 72, 81, 82v, 83, 84, and 89.

^fTest of trend for HPV risk group by p16 IHC result for each diagnosis.